Multivessel Versus Culprit Vessel–Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE‐ACS Observational Study
暂无分享,去创建一个
E. Peterson | G. Fonarow | M. Effron | D. Cohen | Tracy Y. Wang | L. Kaltenbach | Homam Ibrahim | M. Zettler | Praneet K. Sharma | D. Cohen | D. Cohen
[1] Deepak L. Bhatt,et al. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. , 2016, American heart journal.
[2] K. Anstrom,et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study , 2015, European heart journal. Acute cardiovascular care.
[3] L. Køber,et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.
[4] G. Stone,et al. Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] H. Swanton,et al. Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease , 2015, Journal of the American College of Cardiology.
[6] S. Mehta,et al. Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. , 2014, American heart journal.
[7] C. Berry,et al. Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.
[8] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[9] Harlan M Krumholz,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[10] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[11] K. Anstrom,et al. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. , 2011, American heart journal.
[12] D. Holmes,et al. Clinical ResearchInterventional CardiologyCulprit Vessel Only Versus Multivessel and Staged Percutaneous Coronary Intervention for Multivessel Disease in Patients Presenting With ST-Segment Elevation Myocardial Infarction: A Pairwise and Network Meta-Analysis , 2011 .
[13] G. Dangas,et al. Timing of staged percutaneous coronary intervention in multivessel coronary artery disease. , 2010, JACC. Cardiovascular interventions.
[14] P. Armstrong,et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. , 2010, European heart journal.
[15] Samin K. Sharma,et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. , 2010, JACC. Cardiovascular interventions.
[16] G. Sangiorgi,et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up , 2009, Heart.
[17] J. Ottervanger,et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction , 2009, Coronary artery disease.
[18] Emir Veledar,et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). , 2009, The American journal of cardiology.
[19] Deepak L. Bhatt,et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. , 2008, American heart journal.
[20] B. Gersh,et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. , 2007, European heart journal.
[21] M. Hong,et al. Safety of single versus multi-vessel angioplasty for patients with acute myocardial infarction and multi-vessel coronary artery disease: report from the New York State Angioplasty Registry , 2006, Coronary artery disease.
[22] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[23] Mark J Sculpher,et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). , 2005, Journal of the American College of Cardiology.
[24] J. House,et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction , 2005 .
[25] H. Arendrup,et al. Health related quality of life after conservative or invasive treatment of inducible postinfarction ischaemia , 2000 .
[26] F. Ragmin. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.
[27] L. Wallentin,et al. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .
[28] R A Deyo,et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. , 1995, Journal of the American College of Cardiology.